Market Cap 79.74M
Revenue (ttm) 0.00
Net Income (ttm) -73.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 186,200
Avg Vol 240,448
Day's Range N/A - N/A
Shares Out 67.58M
Stochastic %K 44%
Beta -0.16
Analysts Strong Sell
Price Target $9.00

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclo...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 857 2596
Address:
20 William Street, Suite 145, Wellesley Hills, United States
Shane_Drinion
Shane_Drinion Jun. 27 at 4:10 PM
0 · Reply
Kingtan
Kingtan Jun. 18 at 3:38 PM
$CLYM people forgot this shit probably
0 · Reply
vu_jade
vu_jade Jun. 10 at 1:54 PM
$CLYM has to bounce here
0 · Reply
GMoney1776
GMoney1776 Jun. 6 at 8:15 PM
$CLYM Only 38 watchers. People here are in at the ground floor.
0 · Reply
JarvisFlow
JarvisFlow Jun. 6 at 5:10 PM
Oppenheimer has updated their rating for Climb Bio ( $CLYM ) to Outperform with a price target of 10.
0 · Reply
BULLTRADER0007
BULLTRADER0007 Jun. 6 at 12:46 PM
$CLYM Soon $8🚀🚀🚀🚀
0 · Reply
Frustratedshareholder
Frustratedshareholder Jun. 6 at 11:38 AM
$CLYM Happy Friday🚀🚀🔥🔥🔥
0 · Reply
Armonica423
Armonica423 May. 11 at 1:22 AM
$CLYM Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
Frustratedshareholder
Frustratedshareholder Apr. 23 at 9:27 PM
$CLYM Look what happened last time it crossed the 50 day SMA. NOT ADVICE Do your own DD.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 25 at 8:38 PM
$CLYM Climb Bio reports Q4 EPS (13c) vs (13c) last year Cash, cash equivalents and marketable securities were $212.5M as of December 31 as compared to $106.8M as of December 31. Cash, cash equivalents and marketable securities are expected to fund operations through 2027. "2024 was a transformational year for Climb Bio, as we rebranded the company and embarked on our mission to bring more inspired medicines to patients living with immune-mediated diseases," said Aoife Brennan, President and CEO of Climb Bio. "Our momentum continues in 2025, which marks a critical year of execution across our portfolio. Our cornerstone asset, budoprutug, a potentially best-in-class anti-CD19 monoclonal antibody, is being developed for three initial indications: pMN, ITP, and SLE, each of which represents a significant opportunity where we believe budoprutug is differentiated and uniquely positioned to deliver meaningful outcomes for patients. With regulatory clearance from the FDA now in place for clinical trials in all three indications, we have begun initiating clinical trials and expect to begin dosing patients later this year." Dr. Brennan continued, "Additionally, we recently in-licensed a second asset, CLYM116, a potential best-in-class anti-APRIL monoclonal antibody currently in Investigational New Drug -enabling studies for the treatment of IgAN and other B-cell mediated diseases. We remain focused on progressing this program towards the clinic and expect to share initial preclinical data in the second half of 2025. With two highly differentiated assets in our pipeline, a strong balance sheet, and a deeply experienced team, we are well positioned to execute on our goals and advance new treatment options for the approximately 50 million people in the U.S. living with immune-mediated diseases."
0 · Reply
Latest News on CLYM
Climb Bio to Present at Upcoming Investor Conferences

Feb 25, 2025, 7:00 AM EST - 4 months ago

Climb Bio to Present at Upcoming Investor Conferences


Climb Bio to be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 6 months ago

Climb Bio to be Added to the Nasdaq Biotechnology Index


Climb Bio Appoints Douglas E. Williams, Ph.D.

Nov 11, 2024, 7:00 AM EST - 8 months ago

Climb Bio Appoints Douglas E. Williams, Ph.D.


Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 3, 2024, 10:00 AM EDT - 9 months ago

Climb Bio to Host Virtual Investor Event on October 15, 2024


Eliem Therapeutics Announces Additions to its Leadership Team

Aug 26, 2024, 7:00 AM EDT - 11 months ago

Eliem Therapeutics Announces Additions to its Leadership Team


Eliem Therapeutics Reports Second Quarter Financial Results

Aug 14, 2024, 6:05 AM EDT - 11 months ago

Eliem Therapeutics Reports Second Quarter Financial Results


Eliem Therapeutics Provides Update on Pipeline Progress

Oct 5, 2022, 7:00 AM EDT - 2 years ago

Eliem Therapeutics Provides Update on Pipeline Progress


Eliem Therapeutics Provides ETX-810 Program Update

Aug 2, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides ETX-810 Program Update


Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

Apr 25, 2022, 7:00 AM EDT - 3 years ago

Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs


Shane_Drinion
Shane_Drinion Jun. 27 at 4:10 PM
0 · Reply
Kingtan
Kingtan Jun. 18 at 3:38 PM
$CLYM people forgot this shit probably
0 · Reply
vu_jade
vu_jade Jun. 10 at 1:54 PM
$CLYM has to bounce here
0 · Reply
GMoney1776
GMoney1776 Jun. 6 at 8:15 PM
$CLYM Only 38 watchers. People here are in at the ground floor.
0 · Reply
JarvisFlow
JarvisFlow Jun. 6 at 5:10 PM
Oppenheimer has updated their rating for Climb Bio ( $CLYM ) to Outperform with a price target of 10.
0 · Reply
BULLTRADER0007
BULLTRADER0007 Jun. 6 at 12:46 PM
$CLYM Soon $8🚀🚀🚀🚀
0 · Reply
Frustratedshareholder
Frustratedshareholder Jun. 6 at 11:38 AM
$CLYM Happy Friday🚀🚀🔥🔥🔥
0 · Reply
Armonica423
Armonica423 May. 11 at 1:22 AM
$CLYM Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
Frustratedshareholder
Frustratedshareholder Apr. 23 at 9:27 PM
$CLYM Look what happened last time it crossed the 50 day SMA. NOT ADVICE Do your own DD.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 25 at 8:38 PM
$CLYM Climb Bio reports Q4 EPS (13c) vs (13c) last year Cash, cash equivalents and marketable securities were $212.5M as of December 31 as compared to $106.8M as of December 31. Cash, cash equivalents and marketable securities are expected to fund operations through 2027. "2024 was a transformational year for Climb Bio, as we rebranded the company and embarked on our mission to bring more inspired medicines to patients living with immune-mediated diseases," said Aoife Brennan, President and CEO of Climb Bio. "Our momentum continues in 2025, which marks a critical year of execution across our portfolio. Our cornerstone asset, budoprutug, a potentially best-in-class anti-CD19 monoclonal antibody, is being developed for three initial indications: pMN, ITP, and SLE, each of which represents a significant opportunity where we believe budoprutug is differentiated and uniquely positioned to deliver meaningful outcomes for patients. With regulatory clearance from the FDA now in place for clinical trials in all three indications, we have begun initiating clinical trials and expect to begin dosing patients later this year." Dr. Brennan continued, "Additionally, we recently in-licensed a second asset, CLYM116, a potential best-in-class anti-APRIL monoclonal antibody currently in Investigational New Drug -enabling studies for the treatment of IgAN and other B-cell mediated diseases. We remain focused on progressing this program towards the clinic and expect to share initial preclinical data in the second half of 2025. With two highly differentiated assets in our pipeline, a strong balance sheet, and a deeply experienced team, we are well positioned to execute on our goals and advance new treatment options for the approximately 50 million people in the U.S. living with immune-mediated diseases."
0 · Reply
hitmongreen
hitmongreen Mar. 4 at 2:55 PM
$CLYM price action leaves a lot to be desired
1 · Reply
VTHEKING
VTHEKING Mar. 2 at 5:04 PM
$CLYM only 24 watchers wtf.
2 · Reply
kshonstocks
kshonstocks Feb. 26 at 5:48 PM
2.88 in cash $CLYM https://finance.yahoo.com/quote/CLYM/key-statistics/ one to eye
0 · Reply
tradefoxi
tradefoxi Feb. 19 at 11:10 PM
$CLYM Hi Guys The balance sheet of this stock is great there is no negative news like rejections or failures then why is it falling. any info that i missed.
4 · Reply
BioTuesdays
BioTuesdays Feb. 18 at 2:45 PM
Climb Bio is advancing a pipeline of best-in-class, patient-tailored therapeutics to address the unmet needs of complex and clinically-diverse immune-mediated diseases $CLYM https://biotuesdays.com/2025/02/18/climb-driving-transformational-therapies-in-immune-mediated-diseases/
0 · Reply
mrittika1971
mrittika1971 Feb. 1 at 9:16 PM
$CLYM COH: $214.2M which will run the company for 191.8 months, No info on the Balance sheet but Institute owns 81.3% including RA Capital, Blackrock, Vanguard FF: 30.25M, 52w High: 11.55 52W Low: 1.73, current price: 1.90 (develop antibody for IgA Nephropathy)
0 · Reply
hitmongreen
hitmongreen Jan. 14 at 6:48 PM
$CLYM 🤔
1 · Reply
bilocelhi
bilocelhi Jan. 10 at 8:18 PM
$RXRX, keep an 👁️ on $CLYM, a huge volume chunk came in a bit ago, 500 K on 1.5 mil total volume….interesting
0 · Reply
bilocelhi
bilocelhi Jan. 10 at 6:09 PM
$CLYM Climb? You mean descend 😂
0 · Reply
bilocelhi
bilocelhi Jan. 10 at 5:44 PM
$CLYM strange volume, strange price swing…hmmm
0 · Reply
cowgirlbarbie575
cowgirlbarbie575 Jan. 5 at 2:36 AM
Top pick for next week $KUKE 🚀 Watching $PLAG $CLYM closely. Looks like something is brewing 👀👀
0 · Reply
ICUTONIGHTCLUB
ICUTONIGHTCLUB Dec. 31 at 8:46 AM
$CLYM Anybody here?
1 · Reply